Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Forms Neurological Drug Discovery Partnership with Biogen

publication date: Nov 21, 2018

HitGen, a Chengdu drug discovery/development company, announced a discovery research collaboration with Biogen. HitGen will search its DNA-encoded library, which now includes 300 billion novel targets, to identify novel small molecule leads for unspecified neurological disorders. Although Biogen, based in Boston, does not have any operations in China, it partnered with HitGen for discovery, underscoring China's importance in global biopharma development. HitGen will receive an upfront payment and be eligible for milestones, while Biogen will own all rights to the molecules. More details....

Stock Symbol: (NSDQ: BIIB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.